Blar i NILU Brage på forfatter "Mastrokalou, Chara"

Viser treff 1-2 av 2

    • Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models 

      Buociková, Verona; Longhin, Eleonora Marta; Pilalis, Eleftherios; Mastrokalou, Chara; Miklíková, Svetlana; Cihova, Marina; Poturnayova, Alexandra; Mackova, Katarina; Bábelová, Andrea; Trnkova, Lenka; El Yamani, Naouale; Zheng, Congying; Rios-Mondragon, Ivan; Labudova, Martina; Csaderova, Lucia; Kuracinova, Kristina Mikus; Makovicky, Peter; Kučerová, Lucia; Matuskova, Miroslava; Cimpan, Mihaela-Roxana; Dusinska, Maria; Babal, Pavel; Chatziioannou, Aristotelis; Gábelová, Alena; Rundén-Pran, Elise; Smolkova, Bozena (Peer reviewed; Journal article, 2022)
      Acquired drug resistance and metastasis in breast cancer (BC) are coupled with epigenetic deregulation of gene expression. Epigenetic drugs, aiming to reverse these aberrant transcriptional patterns and sensitize cancer ...

    • Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression 

      Buociková, Verona; Tyciakova, Sylvia; Pilalis, Eleftherios; Mastrokalou, Chara; Urbanova, Maria; Matuskova, Miroslava; Demkova, Lucia; Medova, Veronika; Longhin, Eleonora Marta; Rundén-Pran, Elise; Dusinska, Maria; Rios Mondragon, Ivan; Cimpan, Mihaela-Roxana; Gábelová, Alena; Soltysova, Andrea; Smolkova, Bozena; Chatziioannou, Aristotelis (Peer reviewed; Journal article, 2022)
      Decitabine (DAC), a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors. Although epigenome modulation provides a promising ...